DOI: j.jid.2017.11.041 PMID: 29409921
Acne is a multifactorial skin disease, underpinned by colonization of Propionibacterium acnes and inflammation. The emergence of resistant Propionibacterium acnes strains has affected the current acne treatment algorithm. This setback served as an impetus for rationally designing a library of next-generation antibiotics that exhibit a bactericidal effect on resistant Propionibacterium acnes as well as exert an immunomodulatory function to reduce inflammation. In silico screening revealed that one of the molecules, VCD-004, exhibits improved mode of binding to bacterial DNA gyrase. VCD-004 shows high potency against clinical isolates of resistant Propionibacterium acnes, as well as excellent efficacy in vivo. Furthermore, VCD-004 exhibits superior mutant prevention index, suggesting that it impedes the development of resistance better than clindamycin. Additionally, it shows optimal skin penetration and possesses a potent anti-inflammatory effect via reduction of pro-inflammatory cytokines (IL-6) independent of its antibacterial action. Interestingly, VCD-004 affects Propionibacterium acnes-induced nuclear accumulation of NF-κB in THP-1 cells. Notably, the in vitro viability of human keratinocytes in presence of VCD-004 indicates a desirable therapeutic window for topical use. Such rationally designed bactericidal and immunomodulatory dual pharmacophore-based lipophilic molecule(s) can emerge as the next-generation topical therapy for acne with underlying resistant Propionibacterium acnes etiology.
Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, Saini S, Singh H, Kumar D, Kaur SP, Mishra M, Usharani D, Ghosh S, Sengupta S